Omics for Personalized Medicine

- Pharmaco-Geno-Proteo-Metabolomics and Personalized Medicine-An overview
- Personalized genome, current status and the future of harmacogenomic
- Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine
- Pharmaco-epigenomics
- Personalized nutrition and drug-nutrient interactions
- Designing and Implementing Pharmacogenomics Study
- Omics approaches and applications in Clinical Trials
- Ethical Considerations in Pharmacogenomics
- Computational Pharmacogenomics
- Pharmacogenomics in the era of personal genomics: a quick guide to online resources and tools
- Pharmacogenomics and Personalized Medicine for Cancer
- Pharmacogenomics in acute myeloid leukemia
- Pharmacogenomics of autoimmune diseases
- Pharmacogenomics and personalized medicine in Parkinsonism
- Pharmacogenomics and personalized medicine in Alzheimer's disease
- Pharmacogenomics and Personalized Medicine in Mood Disorders
- Pharmacogenetics of opioid and alcohol addiction
- Neurogenetics and Nutrigenomics of Reward Deficiency Syndrome (RDS): Stratification of Addiction Risk and Mesolimbic Nutrigenomic Manipulation of Hypodopaminergic Function
- Pharmacogenomics of analgesics
- Cardiovascular Disease Pharmacogenomics
- Pharmacogenetics of Oral Anticoagulants
- Pharmacogenomics and personalized medicine of the antiplatelet drugs
- Pharmacogenomics of pulmonary and respiratory diseases
- Pharmacogenomics of Allergy and asthma
- Pharmacogenomics in Type 2 Diabetes mellitus and metabolic disorders
- Pharmacogenomics and Gut microbiota biomarkers in Obesity
- Pharmacogenomics and Personalized Medicine for Infectious Diseases
- Pharmacogenomics of Viral diseases
- Pharmacogenomics of osteoporosis-related bone fractures
- Pharmacogenomics of Gynaecological disorders
- Pharmacogenomics and Personalized medicine in Infertility
- Pharmacogenomics in Ophthalmology
- Personalized medicine in Cell Therapy and Transplantation
-

Debmalya Barh is the Founder and President of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India, and a consultant biotechnologist having international repute. He is an active researcher in multidisciplinary "omics" fields that include biomarkers, target and targeted drug discovery, pharmacogenomics, neutrigenomics, neuroscience, cancer, and cardiovascular, infectious, and metabolic diseases. He works with nearly 300 researchers from 18 to 20 countries and has published more than 100 papers. He is a well known editor for many research reference books in the foremost domains of "Omics" published by top-ranked international publishers.

Dipali Dhawan is a promising researcher in the field of Pharmacogenomics, and Induced Pluripotent and Cancer Stem Cells. A postgraduate in Molecular and Genetic Medicine from University of Sheffield, UK and a PhD in Biotechnology from Nirma University, India, Dr. Dhawan is presently associated with the Institute of Life Sciences, Ahmedabad University,  India. She has published many research works and has also been awarded CSIR and DST fellowships.

Prof. Nirmal Kumar Ganguly is a distinguished Biotechnology Research Professor, Department of Biotechnology (DBT), GoI. He is the President of Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), as well as that of the Asian Institute of Public Health, Bhubaneswar, Odisha. He is the former Director General of ICMR, New Delhi, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, and National Institute of Biologicals (NIB), Noida. He has published 757 research papers.  His major areas of research have been Tropical Diseases, Cardiovascular Diseases and Diarrhoeal Diseases. He has received 116 Awards, including 6 International and 110 National Awards. He has been honored with the prestigious Padma Bhushan Award by Her Excellency, the President of India on 26th January 2008 in the field of "Medicine".